Ironwood Pharmaceuticals
IRWD
221 hedge funds and large institutions have $674M invested in Ironwood Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 69 increasing their positions, 77 reducing their positions, and 44 closing their positions.
92,654% more call options, than puts
Call options by funds: $46.4M | Put options by funds: $50K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 226 → 221 (-5)
5.47% less ownership
Funds ownership: 107.8% → 102.34% (-5.5%)
10% less repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 77
11% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 44
40% less capital invested
Capital invested by funds: $1.12B → $674M (-$443M)
Top Buyers
Top Sellers
| 1 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
-$16.8M |
| 2 |
Man Group
London,
United Kingdom
|
-$11.2M |
| 3 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$9.1M |
| 4 |
JP Morgan Chase
New York
|
-$8.31M |
| 5 |
First Eagle Investment Management
New York
|
-$7.2M |
IRWD Hedge Fund Activity: Q3 2024 in Review
221 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q3 2024, worth a combined $674M — down 40% from $1.12B a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of IRWD and 39 opened new positions — a net loss of 5 holders — while 77 trimmed existing stakes and 69 added.
The largest buyer was Pacer Advisors, adding an estimated $12.8M. The largest seller was Brown Capital Management, exiting entirely with an estimated $16.8M sold.
- 221 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q3 2024, down from 226 in Q2 2024.
- Funds reported $674M of Ironwood Pharmaceuticals stock for Q3 2024, down 40% quarter-over-quarter.
- 39 funds opened new Ironwood Pharmaceuticals positions in Q3 2024 and 44 closed out, a net change of -5 holders.
- The largest Ironwood Pharmaceuticals buyer in Q3 2024 was Pacer Advisors, an estimated $12.8M added.
- The largest Ironwood Pharmaceuticals seller in Q3 2024 was Brown Capital Management, an estimated $16.8M sold.
Based on aggregated 13F filings for Q3 2024.